Oncology Institute, Inc. Formerly DFP Healthcare Acquisitions Corp.
Ticker: TOIIW · Form: 8-K · Filed: Apr 3, 2024 · CIK: 1799191
| Field | Detail |
|---|---|
| Company | Oncology Institute, Inc. (TOIIW) |
| Form Type | 8-K |
| Filed Date | Apr 3, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-identity, name-change
TL;DR
Oncology Institute, Inc. used to be DFP Healthcare Acquisitions Corp. - name change Jan 8, 2020.
AI Summary
On April 3, 2024, The Oncology Institute, Inc. filed an 8-K report. The filing indicates that the company was formerly known as DFP Healthcare Acquisitions Corp. and changed its name on January 8, 2020. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This filing clarifies the corporate identity and history of The Oncology Institute, Inc., which is important for investors to understand the entity they are investing in.
Risk Assessment
Risk Level: low — This filing is primarily administrative, confirming a former name and incorporation details, and does not present new financial or operational risks.
Key Players & Entities
- The Oncology Institute, Inc. (company) — Current company name
- DFP Healthcare Acquisitions Corp. (company) — Former company name
- 20200108 (date) — Date of name change
- Delaware (jurisdiction) — State of incorporation
FAQ
What is the current name of the registrant?
The current name of the registrant is The Oncology Institute, Inc.
What was the former name of the company?
The company was formerly known as DFP Healthcare Acquisitions Corp.
When did the company change its name?
The company changed its name on January 8, 2020.
In which state is The Oncology Institute, Inc. incorporated?
The Oncology Institute, Inc. is incorporated in Delaware.
What is the fiscal year end for The Oncology Institute, Inc.?
The fiscal year end for The Oncology Institute, Inc. is December 31.
Filing Stats: 579 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-04-03 16:00:49
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 TOI The Nasdaq Stock Market LLC Redeem
- $11.50 — mon stock, each at an exercise price of $11.50 per share TOIIW The Nasdaq Stock Marke
Filing Documents
- toi-20240403.htm (8-K) — 30KB
- toiinvestorpresentation2.htm (EX-99.1) — 30KB
- toiinvestorpresentation2001.jpg (GRAPHIC) — 73KB
- toiinvestorpresentation2002.jpg (GRAPHIC) — 228KB
- toiinvestorpresentation2003.jpg (GRAPHIC) — 102KB
- toiinvestorpresentation2004.jpg (GRAPHIC) — 100KB
- toiinvestorpresentation2005.jpg (GRAPHIC) — 91KB
- toiinvestorpresentation2006.jpg (GRAPHIC) — 85KB
- toiinvestorpresentation2007.jpg (GRAPHIC) — 101KB
- toiinvestorpresentation2008.jpg (GRAPHIC) — 116KB
- toiinvestorpresentation2009.jpg (GRAPHIC) — 62KB
- toiinvestorpresentation2010.jpg (GRAPHIC) — 62KB
- toiinvestorpresentation2011.jpg (GRAPHIC) — 105KB
- toiinvestorpresentation2012.jpg (GRAPHIC) — 80KB
- toiinvestorpresentation2013.jpg (GRAPHIC) — 54KB
- toiinvestorpresentation2014.jpg (GRAPHIC) — 85KB
- toiinvestorpresentation2015.jpg (GRAPHIC) — 97KB
- toiinvestorpresentation2016.jpg (GRAPHIC) — 78KB
- toiinvestorpresentation2017.jpg (GRAPHIC) — 46KB
- toiinvestorpresentation2018.jpg (GRAPHIC) — 58KB
- toiinvestorpresentation2019.jpg (GRAPHIC) — 99KB
- toiinvestorpresentation2020.jpg (GRAPHIC) — 111KB
- toiinvestorpresentation2021.jpg (GRAPHIC) — 125KB
- 0001628280-24-014573.txt ( ) — 2936KB
- toi-20240403.xsd (EX-101.SCH) — 2KB
- toi-20240403_def.xml (EX-101.DEF) — 16KB
- toi-20240403_lab.xml (EX-101.LAB) — 27KB
- toi-20240403_pre.xml (EX-101.PRE) — 16KB
- toi-20240403_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On April 3, 2024, The Oncology Institute, Inc. (the "Company") issued a slide presentation which includes the Company's financial results for the three months and year ended December 31, 2023 and certain other financial information. A copy of the presentation is furnished hereto as Exhibit 99.1, which are incorporated by reference herein.
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure On April 3, 2024, in conjunction with the slide presentation of its financial results, the Company provided updates regarding the Company's business and guidance for the year ending December 31, 2023. The information provided above in "Item 2.02 - Results of Operations and Financial Condition" of this Current Report on Form 8-K ("Current Report") is incorporated by reference into this Item 7.01. The information contained in Items 2.02 and 7.01 of this Current Report and Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section.
01 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits (d) The following exhibits are being filed herewith: Exhibit No. Description 99.1 Slide presentation issued by The Oncology Institute, Inc. on April 3 , 2 024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 3, 2024 The Oncology Institute, Inc. By: /s/ Mihir Shah Name: Mihir Shah Title: Chief Financial Officer